Halozyme Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Halozyme Therapeutics (HALO).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

2S.Buy

5Buy

3Hold

Consensus RatingMarket Outperform# Analysts10Avg. Consensus PT$83Upside to Avg. PT-25.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 2, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$115
Aug 7, 2026	Leerink Partners	David Risinger	Upgrade	Market Perform→Outperform	$83→$110
Aug 7, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$96→$105
Aug 7, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$92→$93
Aug 7, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$75→$95
Aug 7, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$95→$115
Jul 21, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$95
May 12, 2026	Morgan Stanley	Vikram Purohit	PT Cut	Overweight	$96→$93
Apr 29, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$90→$95
Feb 19, 2026	Benchmark	Robert Wasserman	PT Raise	Buy	$75→$90
Feb 19, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$65→$75
Jan 8, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$79→$90
Dec 19, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$90
Nov 28, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$90
Nov 18, 2025	Goldman Sachs	Graig Suvannavejh	PT Raise	Neutral	$54→$56
Nov 4, 2025	Citizens	Jason Butler	PT Raise	Market Outperform	$91→$92
Oct 27, 2025	JP Morgan	Jessica Fye	PT Raise	Neutral	$63→$65
Oct 20, 2025	Morgan Stanley	Vikram Purohit	PT Cut	Overweight	$80→$79
Oct 15, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$90
Oct 14, 2025	Leerink Partners	David Risinger	Upgrade	Underperform→Market Perform	$70

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $115 price target.

Benzinga Newsdesk

PRO
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93

Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $92 to $93.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weight and raises the price target from $75 to $95.

Benzinga Newsdesk

Atlassian To Rally More Than 63%? Here Are 10 Top Analyst Forecasts For Friday

Wall Street analysts changed ratings & price targets for top stocks. Check out all changes including upgrades & downgrades on Benzinga analyst ratings page.

Avi Kapoor

Halozyme Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Halozyme Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

PRO
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

PRO
Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93

PRO
Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95

Atlassian To Rally More Than 63%? Here Are 10 Top Analyst Forecasts For Friday

People Also Watch

People Also Watch

Halozyme Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Halozyme Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

PROLeerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

PROTD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

PROCitizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93

PROWells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95

Atlassian To Rally More Than 63%? Here Are 10 Top Analyst Forecasts For Friday

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

PRO
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

PRO
Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93

PRO
Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95